

In the substitute specification, please amend the paragraph on page 91,
lines 30-31, to read as follows:

B1A

Polyclonal antibody 1: NDNRERQEHNDRRSL (C) - residues 30-44

In the substitute specification, please amend the paragraph on page 92,
lines 1-2, to read as follows:

B1B

Polyclonal antibody 2: KDGQLIYTPFTEDTE (C) - residues 109-123

In the substitute specification, please amend the paragraph on page 91,
lines 3-4, to read as follows:

B1C

Polyclonal antibody 3: EAQRRVSKNSKYNAE (C) - residues 304-318

IN THE CLAIMS:

Please amend the claims according to 37 C.F.R. 1.121 as follows (see
also accompanying "Mark-Up" pursuant to 37 C.F.R. 1.121):

B2

74. (Amended) The antibody as defined in claim 73, wherein the
mammalian Presenilin protein has a sequence as depicted in SEQ ID NOs:2, 4, 134,
136, or 138.

DD
75. (Amended) The antibody as defined in claim 73, which selectively recognizes an amino acid sequence of at least six contiguous amino acid residues as depicted in SEQ ID NOs:2, 4, 134, 136, or or 138; or antigenic fragments.

B2
76. (Amended) The antibody as defined in claim 75, wherein the antibody selectively recognizes amino acid residues 30-44, 109-123, 304-318, or 346-360 of SEQ ID NO:2.

B3
81. (Amended) The method as defined in claim 80, wherein the mammalian Presenilin protein has a sequence as depicted in SEQ ID NOs: 2, 4, 134, 136, or 138.